CN103328467B - 用作kv3抑制剂的乙内酰脲衍生物 - Google Patents
用作kv3抑制剂的乙内酰脲衍生物 Download PDFInfo
- Publication number
- CN103328467B CN103328467B CN201180058712.3A CN201180058712A CN103328467B CN 103328467 B CN103328467 B CN 103328467B CN 201180058712 A CN201180058712 A CN 201180058712A CN 103328467 B CN103328467 B CN 103328467B
- Authority
- CN
- China
- Prior art keywords
- oxy
- methyl
- imidazolidinedione
- pyridyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)OCc1cc(OCOC)ccc1 Chemical compound C*(C)OCc1cc(OCOC)ccc1 0.000 description 18
- ZRKOWATVZZCKMN-QUXALOBESA-N CC[C@](C)(C(N1c(cn2)ccc2Oc2c(CC(C)CO3)c3ccc2)=O)NC1=O Chemical compound CC[C@](C)(C(N1c(cn2)ccc2Oc2c(CC(C)CO3)c3ccc2)=O)NC1=O ZRKOWATVZZCKMN-QUXALOBESA-N 0.000 description 2
- YIVYHTKWJFMWTR-TWGQIWQCSA-N C/C(/C(C(CC=C1)O)=C1OCOC)=C/CO Chemical compound C/C(/C(C(CC=C1)O)=C1OCOC)=C/CO YIVYHTKWJFMWTR-TWGQIWQCSA-N 0.000 description 1
- SIQUZFBZMJKFMN-WEVVVXLNSA-N C/C(/c(c(O)ccc1)c1O)=N\O Chemical compound C/C(/c(c(O)ccc1)c1O)=N\O SIQUZFBZMJKFMN-WEVVVXLNSA-N 0.000 description 1
- ROVVUKFHORPDSM-UHFFFAOYSA-N CC(C)(C)OC(NC1(CCC1)C(O)=O)=O Chemical compound CC(C)(C)OC(NC1(CCC1)C(O)=O)=O ROVVUKFHORPDSM-UHFFFAOYSA-N 0.000 description 1
- LEYIDJLXQBFPJM-KHPPLWFESA-N CC(C)/C(/c(c(O)ccc1)c1O)=N/O Chemical compound CC(C)/C(/c(c(O)ccc1)c1O)=N/O LEYIDJLXQBFPJM-KHPPLWFESA-N 0.000 description 1
- LAOCCFHGLIBYRK-OUKQBFOZSA-N CC(C)/C(/c(c(O)ccc1)c1O)=N\OC(C)=O Chemical compound CC(C)/C(/c(c(O)ccc1)c1O)=N\OC(C)=O LAOCCFHGLIBYRK-OUKQBFOZSA-N 0.000 description 1
- UHDFMRMASKFTLQ-MRXNPFEDSA-N CC(C)[C@H](C(Nc(cn1)cnc1Oc1c(C(C)(C)CO2)c2ccc1)=O)N Chemical compound CC(C)[C@H](C(Nc(cn1)cnc1Oc1c(C(C)(C)CO2)c2ccc1)=O)N UHDFMRMASKFTLQ-MRXNPFEDSA-N 0.000 description 1
- HHPKSFWUDOWEJB-UHFFFAOYSA-N CC(C)c1n[o]c2cccc(Oc(nc3)ccc3N)c12 Chemical compound CC(C)c1n[o]c2cccc(Oc(nc3)ccc3N)c12 HHPKSFWUDOWEJB-UHFFFAOYSA-N 0.000 description 1
- ACVCJTATWNSJDI-UHFFFAOYSA-N CC(C1C(OC)=CC=CC1O)=O Chemical compound CC(C1C(OC)=CC=CC1O)=O ACVCJTATWNSJDI-UHFFFAOYSA-N 0.000 description 1
- JDFVGECUOPLNPU-UHFFFAOYSA-N CC(CCO)c(c(O)ccc1)c1OCOC Chemical compound CC(CCO)c(c(O)ccc1)c1OCOC JDFVGECUOPLNPU-UHFFFAOYSA-N 0.000 description 1
- DVHRDCBOTLKNGT-UHFFFAOYSA-N CC(CCOc1ccc2)c1c2N Chemical compound CC(CCOc1ccc2)c1c2N DVHRDCBOTLKNGT-UHFFFAOYSA-N 0.000 description 1
- PIYXXJXPHYGNCR-UHFFFAOYSA-N CC(CCOc1ccc2)c1c2OCOC Chemical compound CC(CCOc1ccc2)c1c2OCOC PIYXXJXPHYGNCR-UHFFFAOYSA-N 0.000 description 1
- AVKRESFKGJTDGM-UHFFFAOYSA-N CC(c(c(O1)ccc2)c2OCOC)=CC1=O Chemical compound CC(c(c(O1)ccc2)c2OCOC)=CC1=O AVKRESFKGJTDGM-UHFFFAOYSA-N 0.000 description 1
- WXGPTHAHVOXOQK-UHFFFAOYSA-N CC(c(cc(cc1)Oc(nc2)ccc2N=O)c1C#N)=C Chemical compound CC(c(cc(cc1)Oc(nc2)ccc2N=O)c1C#N)=C WXGPTHAHVOXOQK-UHFFFAOYSA-N 0.000 description 1
- CXFNYJJXKNRKBV-UHFFFAOYSA-N CC1(C)c(c(Oc(cc2)ccc2N)ccc2)c2OC1 Chemical compound CC1(C)c(c(Oc(cc2)ccc2N)ccc2)c2OC1 CXFNYJJXKNRKBV-UHFFFAOYSA-N 0.000 description 1
- SKOFSTJMYBTVII-UHFFFAOYSA-N CC1=CC(O)Oc2cccc(OC)c12 Chemical compound CC1=CC(O)Oc2cccc(OC)c12 SKOFSTJMYBTVII-UHFFFAOYSA-N 0.000 description 1
- OBWBXXDMIXMYEB-UHFFFAOYSA-N CC1COC2=CCCC(Oc(nc3)ccc3NC(C(C)(C)NC(OC(C)(C)C)=O)=O)=C2C1 Chemical compound CC1COC2=CCCC(Oc(nc3)ccc3NC(C(C)(C)NC(OC(C)(C)C)=O)=O)=C2C1 OBWBXXDMIXMYEB-UHFFFAOYSA-N 0.000 description 1
- QECXQPHWKYYYIX-UHFFFAOYSA-N CC1COc2cccc(O)c2C1 Chemical compound CC1COc2cccc(O)c2C1 QECXQPHWKYYYIX-UHFFFAOYSA-N 0.000 description 1
- BSWYSTQZGPPBEL-UHFFFAOYSA-N CC1COc2cccc(Oc(nc3)ccc3NC(C(C)(C)N)=O)c2C1 Chemical compound CC1COc2cccc(Oc(nc3)ccc3NC(C(C)(C)N)=O)c2C1 BSWYSTQZGPPBEL-UHFFFAOYSA-N 0.000 description 1
- CPDWLGQBLZMRST-UHFFFAOYSA-N CCC(C)(C(N1c(cn2)ccc2Oc2c(C3(CC3)CO3)c3ccc2)=O)NC1=O Chemical compound CCC(C)(C(N1c(cn2)ccc2Oc2c(C3(CC3)CO3)c3ccc2)=O)NC1=O CPDWLGQBLZMRST-UHFFFAOYSA-N 0.000 description 1
- FYMQYGBWPNGWNR-UHFFFAOYSA-N CCC(c1c(CO[N](C)(C)C(C)(C)C)cccc1OCOC)OCC Chemical compound CCC(c1c(CO[N](C)(C)C(C)(C)C)cccc1OCOC)OCC FYMQYGBWPNGWNR-UHFFFAOYSA-N 0.000 description 1
- ASKIXEOKKHJMBJ-UHFFFAOYSA-N CCC1OCc2cccc(Oc(nc3)ccc3N)c12 Chemical compound CCC1OCc2cccc(Oc(nc3)ccc3N)c12 ASKIXEOKKHJMBJ-UHFFFAOYSA-N 0.000 description 1
- CWSALOJDOZUOFI-UHFFFAOYSA-N CCC[O](C)COc1cc(CO)ccc1 Chemical compound CCC[O](C)COc1cc(CO)ccc1 CWSALOJDOZUOFI-UHFFFAOYSA-N 0.000 description 1
- NPNNYOLZODHTDE-QNSVNVJESA-N CC[C@H](C(Nc(cc1)cnc1Oc1c(C(CC)OC2)c2ccc1)=O)NC(OC(C)(C)C)=O Chemical compound CC[C@H](C(Nc(cc1)cnc1Oc1c(C(CC)OC2)c2ccc1)=O)NC(OC(C)(C)C)=O NPNNYOLZODHTDE-QNSVNVJESA-N 0.000 description 1
- USKIZFWHJLODHI-MRXNPFEDSA-N CC[C@H](C(Nc(cn1)ccc1Oc(c(C1CC1)c1)ccc1C#N)=O)N Chemical compound CC[C@H](C(Nc(cn1)ccc1Oc(c(C1CC1)c1)ccc1C#N)=O)N USKIZFWHJLODHI-MRXNPFEDSA-N 0.000 description 1
- VTQHJSRQZCGGIA-GICMACPYSA-N CC[C@H](C(Nc(cn1)ccc1Oc1c(C(CC)OC2)c2ccc1)=O)N Chemical compound CC[C@H](C(Nc(cn1)ccc1Oc1c(C(CC)OC2)c2ccc1)=O)N VTQHJSRQZCGGIA-GICMACPYSA-N 0.000 description 1
- IDQDNRHSZGJYAZ-JOCHJYFZSA-N CC[C@](C)(C(N1c(cc2)cnc2Oc2c(CC(C)(C)CO3)c3ccc2)=O)NC1=O Chemical compound CC[C@](C)(C(N1c(cc2)cnc2Oc2c(CC(C)(C)CO3)c3ccc2)=O)NC1=O IDQDNRHSZGJYAZ-JOCHJYFZSA-N 0.000 description 1
- QTUAHSDSCUNWJI-LJQANCHMSA-N CC[C@](C)(C(Nc(cn1)ccc1Oc1c(C2(CC2)CO2)c2ccc1)=O)N Chemical compound CC[C@](C)(C(Nc(cn1)ccc1Oc1c(C2(CC2)CO2)c2ccc1)=O)N QTUAHSDSCUNWJI-LJQANCHMSA-N 0.000 description 1
- CFIIHKMSPXNQAQ-DMPGVRBJSA-N C[C@H](C(Nc(cc1C2(C)CO3)ccc1Oc1c2c3ccc1)=O)N Chemical compound C[C@H](C(Nc(cc1C2(C)CO3)ccc1Oc1c2c3ccc1)=O)N CFIIHKMSPXNQAQ-DMPGVRBJSA-N 0.000 description 1
- SOYWOKSOKVRZRZ-UHFFFAOYSA-N Cc(ccc(O)c1)c1OC Chemical compound Cc(ccc(O)c1)c1OC SOYWOKSOKVRZRZ-UHFFFAOYSA-N 0.000 description 1
- PGEXKVKEKQKZGE-UHFFFAOYSA-N Cc(ccc(Oc(nc1)ccc1[N+]([O-])=O)c1)c1OC Chemical compound Cc(ccc(Oc(nc1)ccc1[N+]([O-])=O)c1)c1OC PGEXKVKEKQKZGE-UHFFFAOYSA-N 0.000 description 1
- HOYFLRISKYZAFS-UHFFFAOYSA-N Cc1n[o]c2cc(C)cc(Oc(cc3)ccc3N)c12 Chemical compound Cc1n[o]c2cc(C)cc(Oc(cc3)ccc3N)c12 HOYFLRISKYZAFS-UHFFFAOYSA-N 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N c1ccnc(SSc2ncccc2)c1 Chemical compound c1ccnc(SSc2ncccc2)c1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1020607.6 | 2010-12-06 | ||
| EPPCT/EP2010/068946 | 2010-12-06 | ||
| PCT/EP2010/068946 WO2011069951A1 (en) | 2009-12-11 | 2010-12-06 | Imidazolidinedione derivatives |
| GBGB1020607.6A GB201020607D0 (en) | 2010-12-06 | 2010-12-06 | Novel compounds |
| GBGB1109508.0A GB201109508D0 (en) | 2011-06-07 | 2011-06-07 | Novel compounds |
| GB1109508.0 | 2011-06-07 | ||
| GBGB1113757.7A GB201113757D0 (en) | 2011-08-10 | 2011-08-10 | Novel compounds |
| GB1113757.7 | 2011-08-10 | ||
| PCT/GB2011/052414 WO2012076877A1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103328467A CN103328467A (zh) | 2013-09-25 |
| CN103328467B true CN103328467B (zh) | 2016-08-10 |
Family
ID=45464001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180058712.3A Active CN103328467B (zh) | 2010-12-06 | 2011-12-06 | 用作kv3抑制剂的乙内酰脲衍生物 |
Country Status (17)
| Country | Link |
|---|---|
| US (13) | US9346790B2 (enExample) |
| EP (1) | EP2649066B1 (enExample) |
| JP (2) | JP5913357B2 (enExample) |
| KR (1) | KR101862375B1 (enExample) |
| CN (1) | CN103328467B (enExample) |
| AU (1) | AU2011340258C1 (enExample) |
| BR (1) | BR112013013914B1 (enExample) |
| CA (1) | CA2817205C (enExample) |
| DK (1) | DK2649066T3 (enExample) |
| EA (2) | EA023768B1 (enExample) |
| ES (1) | ES2560304T3 (enExample) |
| IL (3) | IL226256A0 (enExample) |
| MX (1) | MX338489B (enExample) |
| PL (1) | PL2649066T3 (enExample) |
| SG (2) | SG190203A1 (enExample) |
| WO (1) | WO2012076877A1 (enExample) |
| ZA (1) | ZA201403529B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012015868A2 (pt) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| BR112014028718A2 (pt) * | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| CA2934456C (en) | 2013-12-20 | 2019-01-29 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| PE20161143A1 (es) | 2014-01-16 | 2016-11-18 | Du Pont | Derivados de pirimidiniloxi benceno como herbicidas |
| EP3120140B1 (en) * | 2014-03-21 | 2018-10-31 | Biotage AB | Method and apparatus for the equilibration of a packed chromatography column |
| CN103980205B (zh) * | 2014-06-05 | 2016-01-20 | 武汉格罗宁根医药科技有限公司 | N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用 |
| TWI713530B (zh) | 2015-06-05 | 2020-12-21 | 美商艾佛艾姆希公司 | 作為除草劑之嘧啶氧基苯衍生物 |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) * | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| TW201904947A (zh) * | 2017-05-02 | 2019-02-01 | 美商富曼西公司 | 作為除草劑的嘧啶氧基苯稠合化合物 |
| WO2018220762A1 (ja) | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| CN107556262B (zh) * | 2017-08-14 | 2020-05-22 | 四川大学 | 一种2-取代基芳并噁唑的制备方法 |
| DE112018007799T5 (de) * | 2018-07-03 | 2021-03-25 | Cummins Emission Solutions Inc. | Zersetzungsreaktor mit körpermischung |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| FI3867247T3 (fi) * | 2018-10-16 | 2024-10-30 | Autifony Therapeutics Ltd | Uusia yhdisteitä |
| SG11202104374WA (en) | 2018-11-30 | 2021-05-28 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| GB201821066D0 (en) * | 2018-12-21 | 2019-02-06 | Univ Oxford Innovation Ltd | Sleep modulation |
| AU2019296526A1 (en) * | 2019-03-25 | 2021-09-16 | Bionomics Limited | Substituted-N-heteroaryl compounds and uses thereof |
| BR112022013339A2 (pt) * | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| US11638606B2 (en) | 2020-04-15 | 2023-05-02 | Bard Peripheral Vascular, Inc. | Bipolar electrosurgical pleura sealing device, system, and method of operating same |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
| WO2023017263A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072598A1 (en) * | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3474170A (en) * | 1964-01-23 | 1969-10-21 | Fmc Corp | Pesticidal carbamates of dihydrobenzofuranols |
| US4143055A (en) * | 1978-03-27 | 1979-03-06 | Gruppo Lepetit S.P.A. | 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives |
| DE3015090A1 (de) | 1980-04-19 | 1981-10-22 | Basf Ag, 6700 Ludwigshafen | ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen |
| DE3133405A1 (de) | 1981-08-24 | 1983-03-10 | Basf Ag, 6700 Ludwigshafen | 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide |
| US4675403A (en) | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| JP2514945B2 (ja) * | 1987-02-05 | 1996-07-10 | 三井石油化学工業株式会社 | 芳香族アミン誘導体 |
| DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
| DE3836175A1 (de) | 1988-10-24 | 1990-05-03 | Bayer Ag | Fluor enthaltende phenole |
| CA2007830A1 (en) * | 1989-01-18 | 1990-07-18 | Shuji Ozawa | 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| JPH03153606A (ja) * | 1989-11-10 | 1991-07-01 | Mitsui Petrochem Ind Ltd | 除草剤組成物 |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| DK123493D0 (da) | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
| WO1996036229A1 (en) | 1995-05-17 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| WO1996036633A1 (en) | 1995-05-17 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| CZ394097A3 (cs) | 1995-06-20 | 1998-09-16 | E. I. Du Pont De Nemours And Company | Artropodicidní a fungicidní amidy |
| WO1998005652A2 (en) | 1996-08-01 | 1998-02-12 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| WO1998023156A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Methyl substituted fungicides and arthropodicides |
| AU6040398A (en) | 1997-01-30 | 1998-08-25 | E.I. Du Pont De Nemours And Company | Fungicidal compositions |
| JP4171549B2 (ja) | 1998-01-28 | 2008-10-22 | 大正製薬株式会社 | 含フッ素アミノ酸誘導体 |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| JP2000072731A (ja) | 1998-08-31 | 2000-03-07 | Taisho Pharmaceut Co Ltd | ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物 |
| RU2230551C2 (ru) | 1999-07-23 | 2004-06-20 | ШИОНОГИ энд КО, ЛТД. | Ингибиторы th2-дифференцировки |
| EP1273287A1 (en) | 2000-04-04 | 2003-01-08 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| WO2003048134A1 (en) | 2001-12-05 | 2003-06-12 | Japan Tobacco Inc. | Triazole compound and medicinal use thereof |
| CA2475767A1 (en) | 2002-02-07 | 2003-08-14 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| FI20030030A0 (fi) * | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| ES2290743T3 (es) | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| GB0325175D0 (en) | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| US20060211697A1 (en) | 2004-12-08 | 2006-09-21 | Liren Huang | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| RS52274B2 (sr) | 2005-05-13 | 2018-05-31 | Univ California | Jedinjenje diarilhidantoina |
| PL3412290T3 (pl) | 2006-03-27 | 2021-09-06 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
| CA2648139A1 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| EP2481736A1 (en) | 2007-04-20 | 2012-08-01 | Deciphera Pharmaceuticals, LLC. | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2252592A1 (de) * | 2008-02-07 | 2010-11-24 | Sanofi-Aventis | Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| CA2735842A1 (en) * | 2008-09-02 | 2010-03-11 | Sanofi-Aventis | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| WO2011073114A1 (en) | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| KR20180075650A (ko) | 2015-10-30 | 2018-07-04 | 더 존스 홉킨스 유니버시티 | 고분자량 및 고밀도 코팅을 갖는 점액 침투성 입자 |
-
2011
- 2011-12-06 WO PCT/GB2011/052414 patent/WO2012076877A1/en not_active Ceased
- 2011-12-06 ES ES11805571.4T patent/ES2560304T3/es active Active
- 2011-12-06 BR BR112013013914-5A patent/BR112013013914B1/pt active IP Right Grant
- 2011-12-06 MX MX2013006343A patent/MX338489B/es active IP Right Grant
- 2011-12-06 SG SG2013035357A patent/SG190203A1/en unknown
- 2011-12-06 PL PL11805571T patent/PL2649066T3/pl unknown
- 2011-12-06 AU AU2011340258A patent/AU2011340258C1/en active Active
- 2011-12-06 CN CN201180058712.3A patent/CN103328467B/zh active Active
- 2011-12-06 DK DK11805571.4T patent/DK2649066T3/en active
- 2011-12-06 KR KR1020137017537A patent/KR101862375B1/ko active Active
- 2011-12-06 EA EA201390609A patent/EA023768B1/ru not_active IP Right Cessation
- 2011-12-06 JP JP2013542606A patent/JP5913357B2/ja active Active
- 2011-12-06 US US13/991,486 patent/US9346790B2/en active Active
- 2011-12-06 CA CA2817205A patent/CA2817205C/en active Active
- 2011-12-06 EP EP11805571.4A patent/EP2649066B1/en active Active
-
2012
- 2012-12-06 SG SG11201402529RA patent/SG11201402529RA/en unknown
- 2012-12-06 EA EA201490922A patent/EA027532B1/ru not_active IP Right Cessation
- 2012-12-06 US US14/361,510 patent/US9133175B2/en active Active
-
2013
- 2013-05-09 IL IL226256A patent/IL226256A0/en unknown
-
2014
- 2014-05-15 ZA ZA2014/03529A patent/ZA201403529B/en unknown
-
2015
- 2015-08-03 US US14/816,476 patent/US9422272B2/en active Active
-
2016
- 2016-02-10 JP JP2016023519A patent/JP6118927B2/ja active Active
- 2016-04-07 US US15/093,004 patent/US20160251340A1/en not_active Abandoned
- 2016-07-11 US US15/206,465 patent/US9833452B2/en active Active
-
2017
- 2017-06-13 US US15/621,400 patent/US10265316B2/en active Active
- 2017-06-22 IL IL253104A patent/IL253104A0/en unknown
- 2017-06-22 IL IL253102A patent/IL253102B/en active IP Right Grant
- 2017-10-11 US US15/730,559 patent/US10098881B2/en active Active
-
2018
- 2018-09-07 US US16/125,148 patent/US10555945B2/en active Active
-
2019
- 2019-02-26 US US16/285,996 patent/US20190192516A1/en not_active Abandoned
- 2019-12-23 US US16/725,709 patent/US10835534B2/en active Active
-
2020
- 2020-08-04 US US16/985,160 patent/US11197859B2/en active Active
- 2020-09-23 US US17/030,268 patent/US11541052B2/en active Active
-
2021
- 2021-11-02 US US17/517,620 patent/US11583527B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072598A1 (en) * | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
| CN102753533A (zh) * | 2009-12-11 | 2012-10-24 | 奥蒂福尼疗法有限公司 | 咪唑烷二酮衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103328467B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| CN103974944B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| CN104334547B (zh) | 作为kv3抑制剂的三唑类 | |
| CN103596943B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| JP7036725B2 (ja) | Ｋｖ３チャネルのヒダントインモジュレーター | |
| TWI827706B (zh) | 新穎化合物 | |
| TW201425296A (zh) | 經取代之雜環衍生物 | |
| HUP0401750A2 (hu) | Cinnamidszármazékok mint KCNQ káliumcsatorna-modulátorok és ezeket tartalmazó gyógyszerkészítmények | |
| HK1190395B (en) | Hydantoin derivatives useful as kv3 inhibitors | |
| HK1203072B (en) | Hydantoin derivatives useful as kv3 inhibitors | |
| BR112014013400B1 (pt) | Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |